Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Position Boosted by Atria Investments Inc

Atria Investments Inc increased its holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 19.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,732 shares of the specialty pharmaceutical company’s stock after purchasing an additional 445 shares during the quarter. Atria Investments Inc’s holdings in Jazz Pharmaceuticals were worth $336,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also made changes to their positions in JAZZ. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Jazz Pharmaceuticals by 135.3% in the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company’s stock valued at $19,394,000 after purchasing an additional 100,112 shares during the period. Centre Asset Management LLC purchased a new stake in Jazz Pharmaceuticals during the fourth quarter valued at about $9,335,000. Moloney Securities Asset Management LLC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter worth about $464,000. Pacer Advisors Inc. increased its position in shares of Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company’s stock worth $233,892,000 after acquiring an additional 278,465 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in shares of Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company’s stock valued at $124,208,000 after acquiring an additional 48,708 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Performance

Shares of JAZZ opened at $140.22 on Tuesday. The firm has a market cap of $8.52 billion, a price-to-earnings ratio of 19.75, a price-to-earnings-growth ratio of 1.04 and a beta of 0.44. The company’s fifty day moving average is $129.88 and its 200-day moving average is $121.01. The company has a quick ratio of 3.74, a current ratio of 4.26 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12 month low of $99.06 and a 12 month high of $148.06.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, EVP Neena M. Patil sold 3,800 shares of the business’s stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $144.87, for a total value of $550,506.00. Following the completion of the sale, the executive vice president now owns 33,318 shares of the company’s stock, valued at $4,826,778.66. The trade was a 10.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $122.31, for a total value of $183,465.00. Following the transaction, the chief executive officer now directly owns 439,744 shares in the company, valued at approximately $53,785,088.64. This represents a 0.34 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,736 shares of company stock valued at $4,022,825 over the last three months. 4.20% of the stock is currently owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. raised their price objective on shares of Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a research note on Wednesday, February 26th. Wells Fargo & Company raised Jazz Pharmaceuticals from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $130.00 to $170.00 in a research report on Thursday, February 13th. Truist Financial lifted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the company a “buy” rating in a report on Thursday, March 6th. Needham & Company LLC reissued a “buy” rating and issued a $210.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday, March 5th. Finally, UBS Group raised Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and lifted their target price for the company from $145.00 to $179.00 in a research note on Friday, March 7th. One investment analyst has rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $187.71.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.